 |
80 Diseases |  |
201 Trials |
|
201 Trials |  |
5515 News |  |
| «12...1112131415161718192021...6970» |
- |||| letrozole / Generic mfg., Perjeta (pertuzumab) / Roche
Clinical, Combination therapy: #HER2low #PathTwitter #BreastPath #SABCS22 It predicts response to neoadjuvant "Letrozole"in combination with dua HER2 blockade with transtuzumab and pertuzumab in early breast ca (Hormone positive, Her 2 positive) (Twitter) - Jan 19, 2023
- | $RHHBY Tec+Avastin+chemo combo failed in Imagyn-050 Tec+Herceptin+Perjeta+chemo combo failed in Impassion-050 Tec monoRx succeeded in Impower-010, failed in Imvigor-010 & Immotion-010 Tec+Abraxane combo succeeded in Impassion-031 (Twitter) - Jan 19, 2023
- || Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy, Metastases: DESTINY-Breast07: A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer (clinicaltrials.gov) - Jan 18, 2023
P1b/2, N=450, Recruiting, Sponsor: AstraZeneca
Trial completion date: Apr 2025 --> Dec 2025 | Trial primary completion date: Apr 2025 --> Dec 2024
- ||| Perjeta (pertuzumab) / Roche
Clinical, Clinical data: Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzu… https://t.co/1BlVXxnBz8 Just to fuel the debate around optimal treatment of isolated CNS progression😉 (Twitter) - Jan 15, 2023
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical: Watch: @stolaney1, of @DanaFarber, reviews data from the APHINITY trial regarding the pertuzumab plus trastuzumab and chemotherapy treatment regimen for patients with HER2+ breast cancer. #bcsm #Oncology https://t.co/tXeK1Vsrw7 (Twitter) - Jan 13, 2023
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Review, Journal: Multimodality Imaging Review of HER2-positive Breast Cancer and Response to Neoadjuvant Chemotherapy. (Pubmed Central) - Jan 13, 2023
The authors review the initial manifestations of HER2-positive tumors, the varied responses to neoadjuvant chemotherapy, and the challenges in assessing residual cancer burden through a multimodality imaging review with pathologic correlation. RSNA, 2023 Quiz questions for this article are available through the Online Learning Center.
- ||||| Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Clinical: Our new article led by Dr. de Haas and the entire translation commitee of the KRISTINE trial is out in @BCRJournal High ERBB2 mRNA + immune infiltration predict response to T-DM1+pertuzumab in HER2+ breast cancer https://t.co/bgEdcgBSSD @hospitalclinic @idibaps @UniBarcelona (Twitter) - Jan 12, 2023
- ||| Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Biomarker, P3 data, Journal, PD(L)-1 Biomarker, IO biomarker: Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE). (Pubmed Central) - Jan 12, 2023
P3
Although our biomarker analysis did not identify a subgroup of patients that benefited from neoadjuvant T-DM1 + P versus TCH + P, the data revealed that patients with higher HER2 amplification/expression and immune marker levels had improved response irrespective of treatment arm. These analyses confirm the role of HER2 tumor biology and the immune microenvironment in influencing pCR in the neoadjuvant setting and reaffirm the molecular diversity of HER2-positive breast cancer.
- || Trial completion date, Trial primary completion date, Tumor mutational burden, Pan tumor: Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (clinicaltrials.gov) - Jan 11, 2023
P2, N=720, Recruiting, Sponsor: Canadian Cancer Trials Group
These analyses confirm the role of HER2 tumor biology and the immune microenvironment in influencing pCR in the neoadjuvant setting and reaffirm the molecular diversity of HER2-positive breast cancer. Trial completion date: Sep 2023 --> Jan 2027 | Trial primary completion date: Jun 2023 --> Jan 2026
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Surgery, Metastases: SWOG S1613: S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 10, 2023
P2, N=240, Active, not recruiting, Sponsor: Southwest Oncology Group
Trial completion date: Sep 2023 --> Jan 2027 | Trial primary completion date: Jun 2023 --> Jan 2026 Trial primary completion date: Nov 2023 --> Nov 2022
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date, FDG PET: PHERGain: Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. (clinicaltrials.gov) - Jan 10, 2023
P2, N=377, Active, not recruiting, Sponsor: MedSIR
Trial primary completion date: Nov 2023 --> Nov 2022 Trial completion date: Nov 2022 --> Nov 2023 | Trial primary completion date: Nov 2022 --> Nov 2023
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal, Metastases: Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer. (Pubmed Central) - Jan 10, 2023
The addition of ET to first-line dual anti-HER2 therapy post chemotherapy in patients with HER2 + /HR + MBC was associated with major gains in PFS and OS with no safety concerns evident. Further studies of this combination are justified, along with studies of how best to integrate other agents that are active in this patient subset, including CDK4/6 inhibitors.
- || Kadcyla (ado-trastuzumab emtansine) / Roche, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Perjeta (pertuzumab) / Roche
Review, Journal, Metastases: Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends. (Pubmed Central) - Jan 9, 2023
The standard of care was dual blockade with trastuzumab and pertuzumab as first-line followed by TDM-1 as second-line...Notably, the development of new-generation ADCs has led to unprecedented results compared with T-DM1, currently establishing trastuzumab deruxtecan as a new standard of care in second-line...Response rate and overall life expectancy decrease with each additional line of treatment, and tumor heterogeneity remains an issue. In this review, we update the new-targeted therapeutic options for HER2-positive BC and highlight the future perspectives of treatment in this setting.
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Review, Journal: Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer. (Pubmed Central) - Jan 9, 2023
To improve the therapeutic efficacy of the current strategy, many clinical trials with various HER2-targeted agents are ongoing. This review discusses the molecular basis of HER2-targeted therapeutic strategies for patients with HER2-positive mCRC.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Biomarker, Journal: Evaluating Cardiotoxicity in Breast Cancer Patients Treated with HER2 Inhibitors: Could a Combination of Radionuclide Ventriculography and Cardiac Biomarkers Predict the Cardiac Impact? (Pubmed Central) - Jan 9, 2023
ST2/IL-33R proved statistically significant at the T1 time point (r = -0.547). (4) A combination of LVEF, NT-proBNP and ST2/IL-33R assessment may be useful for early detection of cardiac impairment in breast cancer patients treated with trastuzumab, pertuzumab and docetaxel.
- | Enrollment open, Trial completion date, Trial primary completion date: RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer (clinicaltrials.gov) - Jan 9, 2023
P1/2, N=48, Recruiting, Sponsor: Georgetown University
(4) A combination of LVEF, NT-proBNP and ST2/IL-33R assessment may be useful for early detection of cardiac impairment in breast cancer patients treated with trastuzumab, pertuzumab and docetaxel. Not yet recruiting --> Recruiting | Trial completion date: Nov 2023 --> Nov 2024 | Trial primary completion date: Nov 2023 --> Nov 2024
- ||| Enrollment closed: CUPISCO: A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (clinicaltrials.gov) - Jan 9, 2023
P2, N=790, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting | Trial completion date: Nov 2023 --> Nov 2024 | Trial primary completion date: Nov 2023 --> Nov 2024 Recruiting --> Active, not recruiting
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal, Combination therapy: Additional effect of anthracycline in preoperative chemotherapy with a sequential anthracycline‑containing regimen preceded by pertuzumab, trastuzumab and docetaxel combination therapy. (Pubmed Central) - Jan 7, 2023
Since cardiotoxicity remains a significant problem, a higher risk-benefit treatment strategy is required to aim for AC omission. Trial registration number: UMIN000046338, name of registry: UMIN-CTR, date of registration: December 10, 2021.
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Review, Journal: Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer. (Pubmed Central) - Jan 6, 2023
In this review, we provide an overview of the role of natural killer (NK) cells and ADCC in targeted therapy of HER2-positive breast cancer, including the biological functions of NK cells and the role of NK cells and ADCC in anti-HER2 targeted drugs. We then discuss regulatory mechanisms and recent strategies to leverage our knowledge of NK cells and ADCC as an immunotherapy approach for HER2-positive breast cancer.
- | Trial completion date, Trial primary completion date, Tumor mutational burden: CRAFT: The NCT-PMO-1602 Phase II Trial (clinicaltrials.gov) - Jan 4, 2023
P2, N=175, Recruiting, Sponsor: German Cancer Research Center
We then discuss regulatory mechanisms and recent strategies to leverage our knowledge of NK cells and ADCC as an immunotherapy approach for HER2-positive breast cancer. Trial completion date: Apr 2024 --> Jun 2025 | Trial primary completion date: Apr 2024 --> Jun 2025
- || EG1206A (pertuzumab biosimilar) / EirGenix
Enrollment closed: A Pharmacokinetic Study Comparing EG1206A and Perjeta (Pertzumab) in Healthy Male Volunteers (clinicaltrials.gov) - Jan 3, 2023
P1, N=135, Active, not recruiting, Sponsor: EirGenix, Inc.
Trial completion date: Apr 2024 --> Jun 2025 | Trial primary completion date: Apr 2024 --> Jun 2025 Recruiting --> Active, not recruiting
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma
Review, Journal: Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer. (Pubmed Central) - Dec 30, 2022
The antibody-drug conjugates adotrastuzumab, emtansine, famtrastuzumab, and deruxtecan, as well as the anti-HER2 monoclonal antibody pertuzumab are used in both early-stage and metastatic situations, either alone or in conjunction with chemotherapy and other HER2-targeting therapies...Anti-HER2 ligands can be used in various nano formulations to target HER2 receptors. Here we will discuss, targeted TKIs in patients with HER2+ BC, clinical studies of HER2+ targeted TKIs, mechanisms of resistance to HER2-directed therapies with new implications of TKIs in HER2+ MBC (metastatic breast cancer) and anti-HER2 ligand in various nano formulations to target HER2 receptors.
- Pre-adipocyte-driven NRG1 promotes resistance to FGFR3 inhibition in urothelial carcinoma (Pink Area, Coral 3) - Dec 27, 2022 - Abstract #EAU2023EAU_1877;
- | Perjeta (pertuzumab) / Roche
Journal: Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. (Pubmed Central) - Dec 23, 2022
We discuss the implications for Canadian patients with HER2+ early breast cancer due to a second and final negative funding decision by the Canadian Agency for Drugs and Technologies in Health (CADTH) related to neoadjuvant pertuzumab. This decision will have adverse impacts for up to 1 in 6 women receiving neoadjuvant therapy for high-risk HER2+ breast cancer, due to suboptimal pCR rates and higher risks of invasive breast cancer recurrent events, resulting in the need for more toxic adjuvant therapy.
- | Perjeta (pertuzumab) / Roche
Journal, Combination therapy, Real-world evidence, Real-world: Neoadjuvant Trastuzumab and Pertuzumab in Combination with Standard Chemotherapy for HER2-Positive Early Breast Cancer: Real-World Practice in Cuba. (Pubmed Central) - Dec 23, 2022
This decision will have adverse impacts for up to 1 in 6 women receiving neoadjuvant therapy for high-risk HER2+ breast cancer, due to suboptimal pCR rates and higher risks of invasive breast cancer recurrent events, resulting in the need for more toxic adjuvant therapy. Neoadjuvant trastuzumab (SC) and pertuzumab plus chemotherapy for HER2+ early-stage BC showed benefits in a real-life setting, with an acceptable safety profile.
- |||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Perjeta (pertuzumab) / Roche
Clinical, Monotherapy, Metastases: Dr. Erika Hamilton @ErikaHamilton9 @SarahCannonDocs discussing Dose-Expansion Study DESTINY-Breast07: T-DXd as Monotherapy or Combined With #Pertuzumab in pts With Metastatic #HER2+ #breastcancer from #SABCS22 #bcsm #mBC #VuMedi #OncTwitter #MedTwitter https://t.co/L5WNg52ek2 (Twitter) - Dec 22, 2022
- || Trial completion date, Trial primary completion date, Tumor mutational burden, Metastases: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Dec 21, 2022
P2a, N=670, Active, not recruiting, Sponsor: Genentech, Inc.
Neoadjuvant trastuzumab (SC) and pertuzumab plus chemotherapy for HER2+ early-stage BC showed benefits in a real-life setting, with an acceptable safety profile. Trial completion date: Jan 2023 --> Sep 2023 | Trial primary completion date: Jan 2023 --> Sep 2023
- | Kadcyla (ado-trastuzumab emtansine) / Roche
Observational data, Retrospective data, Journal: Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States. (Pubmed Central) - Dec 21, 2022
Treatment patterns and outcomes appeared comparable for patients who received prior pertuzumab. The short treatment durations and survival with T-DM1 therapy in the real-world setting underscore the need for effective post-trastuzumab therapies.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal, Real-world evidence: Neoadjuvant therapy for early human epidermal growth factor receptor 2 positive breast cancer in China: A multicenter real-world study (CSBrS-015). (Pubmed Central) - Dec 20, 2022
The short treatment durations and survival with T-DM1 therapy in the real-world setting underscore the need for effective post-trastuzumab therapies. Patients in the trastuzumab+pertuzumab group had a higher pCR rate than those in the trastuzumab group, and the toxic side effects were tolerable.
- ||| Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New trial: easy laugh: To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study (clinicaltrials.gov) - Dec 19, 2022
P=N/A, N=204, Recruiting, Sponsor: Shanghai Pudong Hospital
- ||||| Piqray (alpelisib) / Novartis
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: EPIK-B2: Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation (clinicaltrials.gov) - Dec 19, 2022
P3, N=19, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Patients in the trastuzumab+pertuzumab group had a higher pCR rate than those in the trastuzumab group, and the toxic side effects were tolerable. Recruiting --> Active, not recruiting | N=511 --> 19 | Trial completion date: Jul 2031 --> Apr 2024 | Trial primary completion date: Jun 2025 --> Apr 2024
- ||| Perjeta (pertuzumab) / Roche
Clinical: i dont think pertuzumab in the adjuvant setting despite approval has any meaningful clinical benefit. Thoughts? (Twitter) - Dec 17, 2022
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical: Now the treatment plan changes.. 6 cycles of TCH +_ P (pertuzumab costly : so cost issues to patient) followed by 20# RT and maintenance therapy of trastuzumab for remaining 11 cycles followed by hormone therapy for 7 to 10 years (Twitter) - Dec 17, 2022
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
P2 data, Journal: Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer. (Pubmed Central) - Dec 16, 2022
The pCR rate is comparable with docetaxel, carboplatin, trastuzumab, and pertuzumab therapy in the NAT setting, but with fewer treatment-associated toxicities. This finding suggests the possibility of safe avoidance of anthracyclines and carboplatin as components of NAT in patients with HER2+ BC.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal: Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes. (Pubmed Central) - Dec 16, 2022
Using the time-dependent ET variable among patients with ERBB2-targeted therapy with CT, those with maintenance ET had significantly better PFS (hazard ratio, 0.70; 95% CI, 0.60-0.82; P < .001) and OS (hazard ratio, 0.47; 95% CI, 0.39-0.57; P < .001). These results suggest that ET-containing first-line regimens may be associated with benefits among a subgroup of patients with HR+/ERBB2+ MBC.
- || Perjeta (pertuzumab) / Roche
For example CLEOPATRA trial THP vs TH , THP improved mPFS by 6 month but mOS benefit was around 17 month . So is this benefit of OS because of 2nd line treatment or it’s a carry forward effect of pertuzumab (Twitter) - Dec 15, 2022
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche, docetaxel / Generic mfg.
Clinical, Combination therapy: Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer https://t.co/CblbuFoLJs #breastcancer @JIPOEditors @ANaingMD @EditorValerie @DenizCanGuven1 @jibranahmed1 @mirella_nardo @s02shambhavi (Twitter) - Dec 13, 2022
- Tukysa (tucatinib) / Seagen, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
A systematic review to assess the efficacy of HER2-targeted treatment regimens in HER2-positive metastatic colorectal cancer (mCRC). (On Demand | Level 1, West Hall; Poster Board No. J6) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_829;
Long term data are needed to define clinical efficacious based on survival endpoints. >
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613. (On Demand | Level 1, West Hall; Poster Board No. G18) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_803;
P2
Higher level of HER2 amplification may provide a greater degree of clinical benefit from TP compared to CETIRI. Future correlative efforts will explore biomarkers of response/resistance with this strategy.
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Pertuzumab plus trastuzumab (P+T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. (Available On Demand; Poster Board No. C16) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_436;
P2
These data, along with results previously reported by other studies, support continued study of P+T in pts with ERBB2 amplified BTC tumors. Clinical trial information: NCT02693535.
- || inavolisib (GDC-0077) / Roche
Trial completion date, Trial primary completion date, Combination therapy, Metastases: GO39374: To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer (clinicaltrials.gov) - Dec 13, 2022
P1, N=256, Recruiting, Sponsor: Genentech, Inc.
Clinical trial information: NCT02693535. Trial completion date: Dec 2022 --> Nov 2024 | Trial primary completion date: Nov 2022 --> Nov 2024
- ||| Kadcyla (ado-trastuzumab emtansine) / Roche, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
P3 data, Journal: Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. (Pubmed Central) - Dec 12, 2022
P3
Trastuzumab deruxtecan showed a significant improvement in overall survival versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer, as well as the longest reported median progression-free survival, reaffirming trastuzumab deruxtecan as the standard of care in the second-line setting. A manageable safety profile of trastuzumab deruxtecan was confirmed with longer treatment duration.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal: Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer. (Pubmed Central) - Dec 11, 2022
These data found a positive association between the HER2/CEP17 FISH ratio and pCR following neoadjuvant dual HER2-targeted therapy without chemotherapy. Larger prospective studies are needed to validate the HER2 ratio as a biomarker to select patients for neoadjuvant dual anti-HER2 therapy without chemotherapy.
- ||||| Perjeta (pertuzumab) / Roche
Clinical: A timely question in #HER2 is with how well we are doing with novel targeted agents, are their patients who don't need chemo? Who needs pertuzumab? Why 1 year? #SABCS22 @OncoAlert (Twitter) - Dec 10, 2022
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
8 years on Herceptin/Perjeta & my *well-tolerated* drugs have resulted in 8 years of diarrhea (mostly manage), heart ??, CIPN—all affecting me acutely at times & always as a difficult to express lower QOL. Would like acknowledgment of what well-tolerated actually means (Twitter) - Dec 7, 2022
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date, Surgery, Metastases: SWOG S1613: S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 7, 2022
P2, N=240, Active, not recruiting, Sponsor: Southwest Oncology Group
Larger prospective studies are needed to validate the HER2 ratio as a biomarker to select patients for neoadjuvant dual anti-HER2 therapy without chemotherapy. Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Nov 2022 --> Nov 2023
- | New P2 trial: Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer (clinicaltrials.gov) - Dec 6, 2022
P2, N=236, Not yet recruiting, Sponsor: Shengjing Hospital
- |||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical: WATCH: @stolaney1, of @DanaFarber, reviews data from the APHINITY trial regarding the pertuzumab plus trastuzumab and chemotherapy treatment regimen for patients with HER2+ breast cancer. #bcsm #oncology https://t.co/k6FZtL258n (Twitter) - Dec 5, 2022
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical, P3 data, Journal: Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study. (Pubmed Central) - Dec 5, 2022
P3
Safety remained consistent with the known pertuzumab profile. Overall, PUFFIN contributes to the totality of data with pertuzumab in previously untreated HER2-positive locally recurrent or metastatic breast cancer and supports the favorable benefit-risk profile of pertuzumab in Chinese patients.
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
This is called as ever Greening . To keep patent alive. By changing route of administration. Same was done by Roche for Trastuzumab and for Pertuzumab. This is making fool of regulatory authorities to keep the monopoly going.@JackWestMD @darioT_ @US_FDA @drdgoldstein @cspramesh (Twitter) - Dec 3, 2022